The University of Birmingham in the UK is set to launch the CATALYST trial this week to evaluate various drugs for the treatment of Covid-19 patients.
CATALYST will involve drugs targeting the most serious symptoms. This mechanism is expected to mitigate disease severity, decreasing the number of patients requiring intensive care admission.
Go deeper with GlobalData
A series of new drugs will be tested in the trial, including existing medicines for cancer and inflammatory diseases such as rheumatoid arthritis.
